Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins

Vaccine

Volumn 36, Issue 5, 2018, Pages 683-690

  Wang, Min ^a   Jokinen, Jenny ^a   Tretyakova, Irina ^b   Pushko, Peter ^b   Lukashevich, Igor S ^a  

^a University of Louisville School of Medicine   (United States)

^b Medigen Inc   (United States)

Author keywords

Alphavirus replicons; Multivalent Lassa virus vaccine; T cells cross reactivity, protection

Indexed keywords

CD8 ANTIGEN; DRUG VEHICLE; GLYCOPROTEIN P 15095; MULTIVALENT LASSA VIRUS VACCINE; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS GLYCOPROTEIN; VIRUS LIKE PARTICLE VECTOR; VIRUS RNA; VIRUS VACCINE; VIRUS VECTOR; CAPSID PROTEIN; GLYCOPROTEIN; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CLADISTICS; CONTROLLED STUDY; CROSS PRESENTATION; CROSS PROTECTION; CROSS REACTION; DENDRITIC CELL; DRUG DESIGN; DRUG EFFICACY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; LASSA FEVER; LASSA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPLICON; UPREGULATION; VACCINATION; VACCINE IMMUNOGENICITY; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS PARTICLE; ALPHAVIRUS; ANIMAL; CELL LINE; CHLOROCEBUS AETHIOPS; CHO CELL LINE; CRICETULUS; DISEASE MODEL; GENE EXPRESSION; GENE VECTOR; GENETICS; IMMUNIZATION; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE SUBPOPULATION; VERO CELL LINE;

ALPHAVIRUS; ANIMALS; ANTIBODIES, VIRAL; APOPTOSIS; CAPSID PROTEINS; CELL LINE; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETULUS; CROSS REACTIONS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GENETIC VECTORS; GLYCOPROTEINS; IMMUNIZATION; IMMUNOGENICITY, VACCINE; LASSA FEVER; LASSA VIRUS; MICE; REPLICON; T-LYMPHOCYTE SUBSETS; VACCINES, VIRUS-LIKE PARTICLE; VERO CELLS; VIRAL VACCINES;

EID: 85039041289     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.12.046     Document Type: Article

References (41)

1. Radoshitzky, S.R., Bào, Y., Buchmeier, M.J., Charrel, R.N., Clawson, A.N., Clegg, C.S., et al. Past, present, and future of arenavirus taxonomy. Arch Virol 160 (2015), 1851–1874.
2. Fichet-Calvet, E., Rogers, D.J., Risk maps of lassa fever in West Africa. PLoS Negl Trop Dis, 3(3), 2009 doi: e38810.1371/journal.pntd.0000388.
3. Peterson, A.T., Moses, L.M., Bausch, D.G., Mapping transmission risk of Lassa fever in West Africa: the importance of quality control, sampling bias, and error weighting. PLoS One, 9(8), 2014, e100711.
4. Sogoba, N., Feldmann, H., Safronetz, D., Lassa fever in West Africa: evidence for an expanded region of endemicity. Zoonoses Public Health 59 (2012), 43–47 Epub.
5. Richmond, J.K., Deborah, J.B., Lassa fever: epidemiology, clinical features, and social consequences. BMJ 327:7426 (2003), 1271–1275.
6. Falzarano, D., Feldmann, H., Vaccines for viral hemorrhagic fevers - progress and shortcomings. Curr Opin Virol 3 (2013), 1–9.
7. WHO. 2017 Annual review of diseases prioritized under the Research and Development Blueprint, Geneva, Switzerland. < http://wwwwhoint/csr/research-and-development/documents/2017-Prioritization-Long-Reportpdf?ua=1.2017> (24-25 January 2017).
8. Lukashevich, I.S., Stelmakh, T.A., Golubev, V.P., Stchesljonok, E.P., Shkolina, T.V., Ribonucleic acids of Machupo and Lassa viruses. Arch Virol 79 (1984), 189–203.
9. Lukashevich, I.S., Salvato, M.S., Lassa virus genome. Curr Genom 7 (2006), 351–379.
10. Burri, D.J., da Palma, J.R., Kunz, S., Pasquato, A., Envelope glycoprotein of arenaviruses. Viruses 4 (2012), 2162–2181.
11. Fisher-Hoch, S.P., McCormick, J.B., Lassa fever vaccine: a review. Expert Rev Vaccines, 3, 2004, 103, 10.1586/14760584.3.2.189.
12. Jiang, X., Dalebout, T.J., Bredenbeek, P.J., Carrion, R. Jr, Brasky, K., Patterson, J., et al. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 29:6 (2011), 1248–1257.
13. Bowen, M., Rollin, P., Ksiazek, T., Hustad, H., Bausch, D., Demby, A., et al. Genetic diversity among Lassa virus strains. J Virol 74:15 (2000), 6992–7004.
14. Andersen Kristian, G., Shapiro, B.J., Matranga Christian, B., Sealfon, R., Lin Aaron, E., Moses Lina, M., et al. Clinical sequencing uncovers origins and evolution of lassa virus. Cell 162:4 (2015), 738–750, 10.1016/j.cell.2015.07.020.
15. Emmerich, P., Gunter, S., Schmitz, H., Strain-specific antibody response to Lassa virus in the local population of West AFrica. J Clin Virol 42:1 (2008), 40–44.
16. McCormick, J.B., Fisher-Hoch, S.P., Lassa fever. Curr Top Microbiol Immunol 262 (2002), 75–109.
17. Carrion, R. Jr, Patterson, J.L., Johnson, C., Gonzales, M., Moreira, C.R., Ticer, A., et al. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25:20 (2007), 4093–4102.
18. Lukashevich, I.S., Patterson, J., Carrion, R., Moshkoff, D., Ticer, A., Zapata, J., et al. A live attenuated vaccine for lassa fever made by reassortment of lassa and mopeia viruses. J Virol 79:22 (2005), 13934–13942.
19. Pushko, P., Tretyakova, I., Aphavirus replicon vectors for prophylactic applications and cancer intervention. Lukashevich, I.S., Shirwan, H., (eds.) Novel technologies for vaccine development, 2014, Springer, Wienn, 61–85.
20. Pittman, P.R., Makuch, R.S., Mangiafico, J.A., Cannon, T.L., Gibbs, P.H., Peters, C.J., Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14:4 (1996), 337–343.
21. Carrion, R., Bredenbeek, P., Jiang, X., Tretyakova, I., Pushko, P., Lukashevich, I.S., Vaccine platforms to control arenaviral hemorrhagic fevers. J Vaccines Vaccination, 3(7), 2012, 1000160.
22. Pushko, P., Geisbert, J., Parker, M., Jahrling, P., Smith, J., Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 75:23 (2001), 11677–11685.
23. Pushko, P., Parker, M., Ludwig, G.V., Davis, N.L., Johnston, R.E., Smith, J.F., Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 2:2 (1997), 389–401.
24. Bredenbeek, P.J., Molenkamp, R., Spaan, W.J.M., Deubel, V., Marianneau, P., Salvato, M.S., et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345:2 (2006), 299–304.
25. Goicochea, M.A., Zapata, J.C., Bryant, J., Davis, H., Salvato, M.S., Lukashevich, I.S., Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. Vaccine 30:8 (2012), 1445–1452.
26. Lukashevich, I.S., Clegg, J.C., Sidibe, K., Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen. J Med Virol 40:3 (1993), 210–217.
27. Hegde, R.S., Ploegh, H.L., Quality and quantity control at the endoplasmic reticulum. Curr Opin Cell Biol 22 (2010), 437–446.
28. Oslowski, C.M., Urano, F., Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol 490 (2011), 71–92.
29. Ron, D., Habener, J.F., CHOP, a novel developmentally regu-lated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 6 (1992), 439–453.
30. Lukashevich, I.S., The search for animal models for Lassa fever vaccine development. Expert Rev Vaccines 12:1 (2013), 71–86.
31. Geisbert, T., Jones, S., Fritz, E., Shurtleff, A., Geisbert, J., Liebscher, R., et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med, 2, 2005, e183, 10.1371/journal.pmed.0020183.
32. Thompson, J.M., Whitmore, A.C., Staats, H.F., Johnston, R.E., Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. Vaccine 26:33 (2008), 4267–4275.
33. Lukashevich, I.S., Advanced vaccine candidates for lassa fever. Viruses 4:11 (2012), 2514–2557.
34. Norbury, C., Basta, S., Donohue, K.B., Tscharke, D.C., Princiotta, M.F., Berglund, P., et al. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 304 (2004), 1318–1321.
35. Huckriede, A., Bungener, L., Holtrop, M., de Vries, J., Waarts, B.-L., Daemen, T., et al. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. Vaccine 22:9–10 (2004), 1104–1113.
36. Schliehe, C., Bitzer, A., van den Broek, M., Groettrup, M., Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. J Virol 86:18 (2012), 9782–9793.
37. Freigang, S., Eschli, B., Harris, N., Geuking, M., Quirin, K., Schrempf, S., et al. A lymphocytic choriomeningitis virus glycoprotein variant that is retained in the endoplasmic reticulum efficiently cross-primes CD8+ T cell responses. Proc Natl Acad Sci USA 104:33 (2007), 13426–13431, 10.1073/pnas.0704423104.
38. Prescott, J.B., Marzi, A., Safronetz, D., Robertson, S.J., Feldmann, H., Best, S.M., Immunobiology of Ebola and Lassa virus infections. Nat Rev Immunol 17:3 (2017), 195–207, 10.1038/nri.2016.138.
39. Mire, C.E., Cross, R.W., Geisbert, J.B., Borisevich, V., Agans, K.N., Deer, D.J., et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med 23:10 (2017), 1146–1149, 10.1038/nm.4396.
40. Meulen, J., Badusche, M., Satoguina, J., Strecker, T., Lenz, O., Loeliger, C., et al. Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology 321:1 (2004), 134–143.
41. ter Meulen, J., Badusche, M., Kuhnt, K., Doetze, A., Satoguina, J., Marti, T., et al. Characterization of human CD4+ T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J Virol 74:5 (2000), 2186–2192.